Showing 21-30 of 37 results for "".
- First, Only US Neurotoxin for Simultaneous Treatment of Upper Facial Lines Gets FDA Approvalhttps://modernaesthetics.com/news/first-only-us-neurotoxin-for-simultaneous-treatment-of-upper-facial-lines-gets-fda-approval/2473638/Merz Aesthetics announced the US Food and Drug Administration approved XEOMIN (incobotulinumtoxinA) as the first and only neurotoxin for the simultaneous treatment of upper facial lines – forehead lines, frown lines, and crow’s feet. XEOMIN was first approved in 2011 f
- Anti-Aging Products Services, Devices Market Experiencing Significant Growthhttps://modernaesthetics.com/news/anti-aging-products-services-devices-market-experiencing-significant-growth/2473618/New research shows the Anti-Aging Products Services and Devices Market is experiencing significant growth. The surge is fueled by consumers desire to look and feel young. The industry’s current valuation is at $60.76 billion in 2024, according to a revised market report by F
- Dermocosmetic Skin Care Market Poised for Exponential Growth into 2031: Reporthttps://modernaesthetics.com/news/dermocosmetics-skin-care-market-poised-for-exponential-growth-reaching-9833-billion-by-2031/2473559/A new market analysis from Coherent Market Insights forecasts growth in the dermocosmetic skin care products market, projecting its value to soar from $56.94 billion in 2024 to $98.33 billion by 2031, with a compound annual growth rate (CAGR) of 8.1%. The primary reason f
- Nulastin Taps Felipe Jimenez, PhD, for Chief Science Officerhttps://modernaesthetics.com/news/nulastin-taps-felipe-jimenez-phd-for-chief-science-officer/2473462/Felipe Jimenez, PhD, is Nulastin’s new Chief Science Officer. Formerly of Benchmark Cosmetic Laboratories (a KDC/One company) and Guthy-Renker, Mr. Jimenez holds more than 30 patents on elastin regeneration. "This is a dream come true having F
- Alma’s Opus Plasma Debuts in North Americahttps://modernaesthetics.com/news/almas-opus-plasma-debuts-in-north-america/2472871/Alma, Inc. is launching Opus in North America. Opus is a new platform featuring the company's proprietary high-frequency unipolar radio-frequency technology, Opus Plasma. Opus Plasma is the first fractional plasma technology to enter the f
- AestheticWires’s Toxin Pipeline Watch: RelabotulinumtoxinA Smoothes Crow’s Feet and Frown Lines Quickly and Results Last in Phase IIIb Studieshttps://modernaesthetics.com/news/aestheticwiress-toxin-pipeline-watch-relabotulinumtoxina-smoothes-crows-feet-and-frown-lines-quickly-and-results-last-in-phase-iiib-studies/2473537/RelabotulinumtoxinA produces rapid and long-lasting effects on crow’s feet and frown kines, according to topline results from two phase IIIb studies. Galderma’s relabotulinumtoxinA is a novel liquid formulation of botulinum toxin A currently being investigated globally.
- Martine Williamson Named Revlon’s New Chief Marketing Officerhttps://modernaesthetics.com/news/martine-williamson-named-revlons-new-chief-marketing-officer/2473025/Martine Williamson is Revlon’s new Chief Marketing Officer. In this role, Williamson will be central to creating and spearheading global strategic plans across the brand portfolio and overseeing Revlon’s overall brand equity and architecture. Williamson officially join
- Happy 30th, Botox!https://modernaesthetics.com/news/happy-30th-botox/2472832/Botox is turning 30, and Allergan fêted its shining star, Botox Cosmetic, in style at a New York City bash. The event included the debut of Botox Cosmetic’s new packaging and a panel discussion featuring New York City dermatologists Macrene Alexiades-Armenakas, MD, PhD
- Edwin Williams, III, MDhttps://modernaesthetics.com/profiles/edwin-williams-iii-md/L2elJB/
- Edwin Williams, MDhttps://modernaesthetics.com/profiles/edwin-williams-md/jmxapy/